Detalhe da pesquisa
1.
Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo.
Sci Transl Med
; 16(734): eadg7962, 2024 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38354229
2.
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.
Oncoimmunology
; 12(1): 2205336, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37114242
3.
Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies.
Oncoimmunology
; 11(1): 2054106, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35355682
4.
Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers.
J Immunother Cancer
; 10(12)2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36564128
5.
Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity.
iScience
; 25(9): 104958, 2022 Sep 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36072551
6.
Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.
Cancer Immunol Res
; 10(4): 498-511, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35362043
7.
Acquired Senescent T-Cell Phenotype Correlates with Clinical Severity in GATA Binding Protein 2-Deficient Patients.
Front Immunol
; 8: 802, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28747912